PO.CL01.14 · 临床研究

整合空间转录组学与蛋白质组学工作流程以实现高分辨率多组学分析

Integrated spatial transcriptomics and proteomics workflows for high-resolution multiomics analysis

海报缩略图:整合空间转录组学与蛋白质组学工作流程以实现高分辨率多组学分析
编号 6667 展板 9 时间 4/21 02:00–05:00 区域 Section 48 主讲 Jan-Philipp Mallm
分会场 Spatial Proteomics and Transcriptomics 3
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Cindy Pamela Ulloa Guerrero1, Michele Bortolomeazzi1, Pooja Sant1, Laura Schütze1, Laura Giese1, Denise Keitel1, Julia Boehl2, Robin Reschke2, Jan-Philipp Mallm1

1Single-cell Open Lab, DKFZ German Cancer Research Center, Heidelberg, Germany,2Max-Eder Research Group Reschke, University Hospital Heidelberg, Heidelberg, Germany

摘要 Abstract

中文摘要
高分辨率组织分析日益依赖整合的空间多组学方法,将空间转录组学与基于抗体的蛋白质组学相统一,以揭示复杂组织内协调的分子模式。这使得对空间生态位、细胞-细胞相互作用和组织微环境的详细探索成为可能。然而,这些模态通常在连续切片上进行,限制了分子特征与空间特征之间的精确关联。在此,我们提出优化的工作流程,以协调且可定制的方式,将高多重成像和基于测序的空间转录组学检测与来自同一组织切片的基于抗体的蛋白质组学相结合。 我们开发并评估了实验性调整,以确保在包括Xenium、Visium和COMET在内的多个平台上实现高数据质量和最佳组织处理。我们实施了质量控制程序以评估抗原修复的兼容性,因为这些条件可能因抗体而异。我们研究了表位暴露、组织完整性和背景信号之间的平衡,针对不同研究目标提供了具体建议。 我们进一步比较了这些技术的灵敏度,并就在可控、灵活的设置中选择和组合市售转录组学与蛋白质组学工作流程提供指导。与所有多组学方法一样,信号丢失可能发生,尤其是在连续分析的第二次读取中。对于蛋白质组学,光漂白和抗原修复是关键考量因素,特别是对于低丰度或难以检测的靶标。转录组学数据可通过在COMET上使用HiPlex RNAscope Pro检测低表达转录本而得到增强。对于数据整合,我们采用了一个简明的流程,包括基于蛋白质数据的细胞分割、使用核染色和/或分割掩膜的图像配准,以及在SpatialData框架内提取单细胞转录本计数和像素强度数据用于下游分析。 我们将这些工作流程应用于扁桃体、皮肤和结肠组织,使用聚焦免疫肿瘤学的panel。这一联合方法提高了分子分辨率并减少了数据稀疏性,能够更精确地定义细胞状态、空间邻域和功能生态位。这些空间多组学工作流程扩展了分析能力,并促进了在多样组织背景下更深入的生物学解读。
查看英文原文 English abstract
High-resolution tissue profiling increasingly relies on integrated spatial multiomic approaches that unify spatial transcriptomics and antibody-based proteomics to reveal coordinated molecular patterns within complex tissues. This enables a detailed exploration of spatial niches, cell-cell interactions, and tissue microenvironments. However, these modalities are often performed on consecutive sections, limiting precise correlation between molecular and spatial features. Here, we present optimized workflows that combine high-plex imaging and sequencing-based spatial transcriptomic assays with antibody-based proteomics from the same tissue section in a coordinated and customizable manner. We developed and evaluated experimental adaptations to ensure high data quality and optimal tissue handling across multiple platforms, including Xenium, Visium, and COMET. Quality control procedures were implemented to assess antigen retrieval compatibility, as these conditions can be antibody dependent. We examined the balance between epitope exposure, tissue integrity, and background signal, providing specific recommendations tailored to different research objectives. We further compared the sensitivity of these technologies and offer guidance on selecting and combining commercially available transcriptomic and proteomic workflows in a controlled, flexible setup. As in all multiomic approaches, signal loss can occur, particularly in the second readout of consecutive analyses. For proteomics, photobleaching and antigen retrieval are key considerations, especially for low-abundance or difficult-to-detect targets. Transcriptomic data can be enhanced by using HiPlex RNAscope Pro on COMET to detect lowly expressed transcripts. For data integration, we employed a straightforward pipeline that includes cell segmentation based on protein data, image registration using nuclear staining and/or segmentation masks, and extraction of single-cell transcript counts and pixel intensity data for downstream analyses within the SpatialData framework. We applied these workflows to tonsil, skin, and colon tissues using immuno-oncology-focused panels. The combined approach improved molecular resolution and reduced data sparsity, enabling more precise definition of cell states, spatial neighborhoods, and functional niches. These spatial multiomics workflows expand the analytical capabilities and facilitate deeper biological interpretation across diverse tissue contexts.
利益披露 Disclosure
C. Ulloa Guerrero, None.. M. Bortolomeazzi, None.. P. Sant, None.. L. Schütze, None.. L. Giese, None.. D. Keitel, None.. J. Boehl, None.. R. Reschke, None. J. Mallm, Lunaphore biotechne ).

← 返回 AACR 2026 检索